Intra-cellular therapies announces the initiation of clinical trials for iti-llai, a long-acting injectable formulation of lumateperone for the treatment of schizophrenia and for iti-333, a novel treatment for opioid use disorder

The company continues expansion of its lumateperone programs with the advancement of a long-acting injectable formulation into clinical trials.

ITCI Ratings Summary

ITCI Quant Ranking